APhase 3, Open-label, Randomized Study to Compare the Efficacy and Safety ofLuspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due toRevised International Prognostic Scoring System (IPSS-R) Very Low, Low, orIntermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulatingAgent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The“ELEMENT-MDS” Trial